Search

Your search keyword '"Hormone-sensitive advanced prostate cancer"' showing total 3 results
Start Over Descriptor "Hormone-sensitive advanced prostate cancer"
3 results on '"Hormone-sensitive advanced prostate cancer"'

1. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Author

Cassinello, J., Arranz, J., Piulats, J., Sánchez, A., Pérez-Valderrama, B., Mellado, B., Climent, M., Olmos, D., Carles, J., and Lázaro, M.

Abstract

Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

3. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Author

Begoña Mellado, Javier Cassinello, David Olmos, Miguel Angel Climent, M. Lázaro, Joan Carles, Josep M. Piulats, J. A. Arranz, A. Sánchez, and Begoña Perez-Valderrama

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Radium 223, medicine.drug_class, Clinical Guides in Oncology, Antineoplastic Agents, Disease, Docetaxel, urologic and male genital diseases, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, Androgen deprivation treatment, 0302 clinical medicine, Internal medicine, medicine, Enzalutamide, Humans, 030212 general & internal medicine, Abiraterone, Castration-resistant prostate cancer, Cabazitaxel, Hormone-sensitive advanced prostate cancer, business.industry, Correction, Prostatic Neoplasms, General Medicine, Prostate carcinoma, medicine.disease, Androgen, chemistry, 030220 oncology & carcinogenesis, business, medicine.drug
Abstract

Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results